A Multicenter, Open-label, Non-randomized Controlled Real World Study Comparing the Benefits of Continued Use of Ovarian Function Suppression After 5 Years
To observe and evaluate the clinical efficacy and safety of continuous use of OFS for premenopausal patients with early breast cancer after 5 years use of OFS. This study is a multicenter, prospective, observational, non randomized controlled, open-label real world study based on hospital medical record system data, aimed at evaluating the benefits of continuing to use OFS after 5 years of use. The retrospective analysis plan includes patient data from September 1, 2023 to September 1, 2026. Join two cohorts: the continued use group and the discontinued use group after 5 years of OFS, respectively.
• Diagnosed with early primary breast cancer
• Female aged 18-60 years (including 18 year and 60 year)
• Hormone receptor (HR) positive HER2 negative
• Receive 5 years of OFS treatment
• ECOG score 0-1
• Voluntarily join this study and sign the informed consent form;
• The researcher believes that it can benefit.